New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:52 EDTREGNRegeneron upgraded to Buy from Neutral at Citigroup
Citigroup upgraded it rating on Regeneron (REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company's Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron's pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron closed Friday up $1.43 to $329.50.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:34 EDTREGNRegeneron bull case weaker but catalysts remain, says UBS
UBS said the bull case for Regeneron weakened following its Q4 earnings miss, citing lower Eylea growth projected for this year. The firm believes that despite the lower results, its earnings ramp is still significant and ample pipeline catalysts remain. UBS reiterated its Buy rating but lowered its price target to $575 from $645 on Regeneron shares.
07:18 EDTREGNRegeneron price target lowered to $489 from $659 at Brean Capital
Subscribe for More Information
February 9, 2016
16:53 EDTREGNOn The Fly: Top stock stories for Tuesday
Stocks began the day sharply lower in the wake of a stock market selloff in Japan, but the domestic averages quickly gathered themselves and were in positive territory before long. From there stocks spent most of the day searching for direction but not moving far from the flat line. A late day rally made it seem like a green close was possible, but the averages could not hold and the market's losing streak continued, though the losses were modest. ECONOMIC EVENTS: In the U.S., wholesale sales dipped 0.3% in December, while inventories fell 0.1%. The Labor Department's Job Openings and Labor Turnover Survey showed job openings rose 261,000 in December to about 5.61M. In Asia, most major markets remain closed for Chinese New Year, but one of the exceptions, Japan, saw its main indexes plunge, as the Nikkei dropped 5.4% and the Topix fell 5.5%. COMPANY NEWS: Class A shares of 21st Century Fox (FOXA) declined 1.85% to $24.14 after the company reported lower than expected second quarter revenue and cut its 2016 outlook, while peer Viacom (VIAB) tumbled 21.5% to $32.86 following its own revenue miss. The largest name in the space, Disney (DIS), rose fractionally ahead of its own earnings report after the bell, but its shares dipped nearly 3% in after-hours trading following the company's report... Deutsche Bank (DB) continued its recent slide, falling another 1% in New York trading despite a report of co-CEO John Cryan telling employees in a memo that the bank is "absolutely rock-solid." The stock came well off its lows in afternoon trading, however, after Financial Times said the German giant is considering buying back several billion euros of its debt... Anadarko Petroleum (APC) lost 7.5% to $37.06 after slashing its dividend to 5c from 27c per share, with Anadarko Chairman and CEO Al Walker defending the step as "the appropriate action to take in the current environment." MAJOR MOVERS: Among the notable gainers was Boston Scientific (BSX), which advanced 5% to $16.87 after announcing that the government's Medicare and Medicaid will cover its Watchman cardiac device. Also higher was Salesforce (CRM), which gained 6.1% to $57.33 after being upgraded to Hold from Underperform at Jefferies, with the research firm arguing that Salesforce is seeing improved traction in enterprise and continued solid mid-market performance. In addition, Wyndham (WYN), Spirit Airlines (SAVE) and Masco (MAS) rose 2.6%, 5.8% and 8.2%, respectively, following their quarterly earnings reports. Among the noteworthy losers was ITC Holdings (ITC), which fell 1.85% to $38.65 after agreeing to be acquired by Fortis in a cash-and-stock deal valued at roughly $11.3B. Also lower were Regeneron (REGN) and Wendy's (WEN), which lost 6.3% and 4.3%, respectively, after announcing their quarterly results. INDEXES: The Dow fell 12.67, or 0.08%, to 16,014.38, the Nasdaq lost 14.99, or 0.35%, to 4,268.76, and the S&P 500 declined 1.23, or 0.07%, to 1,852.21.
12:25 EDTREGNRegeneron price target lowered to $443 from $607 at Piper Jaffray
Subscribe for More Information
09:25 EDTREGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Wendy's (WEN), up 3.5%. ALSO HIGHER: ITC Holdings (ITC), up 1.1% after being acquired by Fortis for in a deal valued at $11.3B... Kinross Gold (KGC), up 2.9% after being upgraded to Outperform from Neutral at Credit Suisse... Boston Scientific (BSX), up 3.1% after announcing that Medicare will cover Watchman left atrial appendage closure Device. DOWN AFTER EARNINGS: Regeneron (REGN), down 7.2%... Twenty-First Century Fox (FOXA, FOX), down 6.7% and 2.6%, respectively... CVS Health (CVS), down 3.5%... Viacom (VIAB), down 3.2%. ALSO LOWER: Constant Contact (CTCT), down 3.3% after Bloomberg reported that Endurance International (EIGI) withdrew a $735M loan Monday that was intended to help fund its $1.1B takeover of the company... Paypal (PYPL), down 2.4% after announcing a Chief Technology Officer transition.
06:33 EDTREGNRegeneron sees FY16 U.S. Eylea revenue up 20% over FY15
06:32 EDTREGNRegeneron reports U.S. Eylea revenue $746M vs. $518M last year
Subscribe for More Information
06:32 EDTREGNRegeneron reports Q4 EPS $2.83, consensus $3.36
Subscribe for More Information
February 8, 2016
14:28 EDTREGNNotable companies reporting before tomorrow's open
Subscribe for More Information
07:25 EDTREGNBiotech Industry Organization to hold a conference
Subscribe for More Information
February 5, 2016
09:26 EDTREGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:06 EDTREGNRegeneron resumed with an Outperform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTREGNRegeneron reinitiated with an Outperform at Leerink
Target $534.
January 29, 2016
13:38 EDTREGNAmgen wins right to allege willful infringement in Praluent suit, Markman says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use